CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

This study is testing a bispecific CAR T-cell therapy — immune cells engineered to attack cancer cells carrying two different markers (CD19 and CD22) — in people with B-cell blood cancers that have come back or stopped responding to treatment. **You may be eligible if...** - You have CD19+ and CD22+ B-cell blood cancer (such as B-cell leukemia or lymphoma) confirmed by testing - Your cancer has relapsed (come back) or is refractory (no longer responding) - You may qualify if you relapsed within 6 months of first remission, didn't respond to standard chemotherapy, or are not eligible for a stem cell transplant **You may NOT be eligible if...** - Your cancer is not CD19+ or CD22+ - You are in good remission and do not require further therapy - You have organ problems that make this treatment unsafe Talk to your doctor to see if this trial is right for you.